| Literature DB >> 35756466 |
Yimin Dai1, Chang Han2,1, Xisheng Weng2.
Abstract
Introduction: The loss of blood is a significant problem in Total Knee Arthroplasty (TKA). Anemia often occurs after such surgeries, leading to serious consequences, such as higher postoperative infection rates and longer hospital stays. Tools for predicting possible anemia can provide additional guidance in realizing better blood management of patients.Entities:
Keywords: ESR; anemia; nomogram; predictors; total knee arthroplasty
Year: 2022 PMID: 35756466 PMCID: PMC9222331 DOI: 10.3389/fsurg.2022.849761
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Basic characteristics of patients from both training and validation cohort.
| Variables | Training cohort | Validation cohort | |||
|---|---|---|---|---|---|
|
| % |
| % | ||
|
|
|
|
| ||
| Age (years) | 0.948 | ||||
| <60 | 206 | (13.6) | 85 | (13.1) | |
| 60–65 | 293 | (19.3) | 135 | (20.8) | |
| 65–70 | 422 | (27.8) | 180 | (27.8) | |
| 70–75 | 302 | (19.9) | 125 | (19.3) | |
| >75 | 294 | (19.4) | 123 | (19.0) | |
| Sex | 0.366 | ||||
| Male | 1,395 | (92.0) | 611 | (94.3) | |
| Female | 122 | (8.0) | 37 | (5.7) | |
| BMI (kg/m2) | 0.136 | ||||
| <24 | 280 | (18.5) | 143 | (22.1) | |
| 24–28 | 655 | (43.0) | 273 | (42.1) | |
| >28 | 584 | (35.8) | 232 | (35.8) | |
| Smoking | 0.069 | ||||
| Yes | 122 | (8.0) | 37 | (5.7) | |
| No | 1,395 | (92.0) | 611 | (94.3) | |
| Drinking | 0.591 | ||||
| Yes | 58 | (3.8) | 21 | (3.2) | |
| No | 1,459 | (96.2) | 627 | (96.8) | |
| Drug | 0.335 | ||||
| Yes | 175 | (11.5) | 85 | (13.1) | |
| No | 1,342 | (88.5) | 563 | (86.9) | |
| Infusion of protein | 0.679 | ||||
| Yes | 408 | (26.9) | 168 | (25.9) | |
| No | 1,109 | (73.1) | 480 | (74.1) | |
| Abnormally high CRP levels | 0.912 | ||||
| Yes | 197 | (13) | 86 | (13.3) | |
| No | 1,320 | (87) | 562 | (86.7) | |
| Abnormally high ESR levels | 0.451 | ||||
| Yes | 357 | (23.5) | 163 | (25.2) | |
| No | 1,160 | (76.5) | 485 | (74.8) | |
| Hb < 12.0 g/dL (male) or <11.0 g/dL (female) (preoperative anemia or not) | 0.861 | ||||
| Yes | 66 | (4.4) | 30 | (4.6) | |
| No | 1,451 | (95.6) | 618 | (95.4) | |
| Sides of TKA | 0.058 | ||||
| One side | 494 | (32.6) | 239 | (36.9) | |
| Two sides | 1,023 | (67.4) | 409 | (63.1) | |
| Number of comorbidities | 0.97 | ||||
| <2 kinds of comorbidities | 732 | (48.3) | 313 | (48.3) | |
| 2 kinds of comorbidities | 385 | (25.4) | 167 | (25.8) | |
| >2 kinds of comorbidities | 400 | (26.4) | 168 | (25.9) | |
| Anemia in three days after operation | 0.778 | ||||
| Yes | 253 | (16.7) | 112 | (17.3) | |
| No | 1,264 | (83.3) | 536 | (82.7) | |
Data are n (%) or mean ± SD. Bold represents p-value of the variable is less than 0.05.
Postoperative anemia of TKA: univariate and multivariate analysis of possible risk factors in the training cohort.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | Adjusted OR (95% CI) | |||
| Age (years) | ||||
| <60 | 1.000 | |||
| 60–65 | 1.131 (0.709–1.804) | 0.605 | ||
| 65–70 | 0.955 (0.617–1.480) | 0.838 | ||
| 70–75 | 0.977 (0.655–1.459) | 0.911 | ||
| >75 | 0.992 (0.644–1.527) | 0.971 | ||
| Sex | ||||
| Female | 1.000 | 1.000 | ||
| Male | 0.440 (0.283–0.686) |
| 0.458 (0.289–0.727) |
|
| Drug | ||||
| No | 1.000 | |||
| Yes | 0.732 (0.461–1.160) | 0.732 | ||
| BMI (kg/m2) | ||||
| <24 | 1.000 | 1.000 | ||
| 24–28 | 0.832 (0.591–1.169) | 0.289 | 0.683 (0.471–0.991) |
|
| >28 | 0.417 (0.284–0.611) |
| 0.312 (0.206–0.473) |
|
| Infusion of protein | ||||
| No | 1 | |||
| Yes | 0.793 (0.590–1.065) | 0.123 | ||
| Abnormally high CRP levels | ||||
| No | 1 | |||
| Yes | 0.880 (0.596–1.299) | 0.520 | ||
| Hb < 12.0 g/dL (male) or <11.0 g/dL (female) (preoperative anemia or not) | ||||
| No | 1 | |||
| Yes | 4.903 (2.962–8.117) |
| 5.671 (3.156–5.714) | |
| Abnormally high ESR levels | ||||
| No | 1.000 | 1.000 | ||
| Yes | 1.537 (1.140–2.073) |
| ||
| Sides of TKA | ||||
| One side | 1 | |||
| Two sides | 3.740 (2.829–4.943) |
| 4.247 (3.156–5.714) |
|
| Number of comorbidities | ||||
| <2 kinds of comorbidities | 1.000 | |||
| 2 kinds of comorbidities | 0.999 (0.714–1.397) | 0.994 | ||
| >2 kinds of comorbidities | 1.162 (0.942–1.602) | 0.361 | ||
| Anemia in three days after operation | ||||
| No | 1,264 (83.3%) | |||
| Yes | 253 (16.7%) | |||
Postoperative anemia of TKA: univariate and multivariate analysis of possible risk factors in the validation cohort.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | Adjusted OR (95% CI) | |||
| Age (years) | ||||
| <60 | 1.000 | |||
| 60–65 | 0.764 (0.385–1.520) | 0.443 | ||
| 65–70 | 0.836 (0.439–1.589) | 0.584 | ||
| 70–75 | 0.709 (0.350–1.437) | 0.340 | ||
| >75 | 0.638 (0.310–1.313) | 0.222 | ||
| Sex | ||||
| Female | 1.000 | 1.000 | ||
| Male | 0.306 (0.138–0.678) |
| 0.399 (0.177–0.900) |
|
| Drug | ||||
| No | 1.000 | |||
| Yes | 0.846 (0.451–1.588) | 0.603 | ||
| BMI (kg/m2) | ||||
| <24 | 1.000 | |||
| 24–28 | 0.747 (0.440–1.266) | 0.278 | ||
| >28 | 0.908 (0.534–1.544) | 0.721 | ||
| Infusion of protein | ||||
| No | 1.000 | |||
| Yes | 0.697 (0.424–1.145) | 0.154 | ||
| Abnormally high CRP levels | ||||
| No | 1.000 | |||
| Yes | 1.211 (0.682–2.152) | 0.514 | ||
| Hb < 12.0 g/dL (male) or <11.0 g/dL (female) (preoperative anemia or not) | ||||
| No | 1.000 | 1.000 | ||
| Yes | 6.214 (2.937–13.15) |
| 6.152 (2.724–13.89) |
|
| Abnormally high ESR levels | ||||
| No | 1.000 | 1.000 | ||
| Yes | 2.160 (1.403–3.326) |
| 1.666 (1.043–2.66) | 0.033 |
| Sides of TKA | ||||
| One side | 1.000 | |||
| Two sides | 2.63 (1.737–3.981) |
| 2.90 (1.866–4.495) |
|
| Number of comorbidities | ||||
| <2 kinds of comorbidities | 1.000 | |||
| 2 kinds of comorbidities | 0.946 (0.570–1.571) | 0.830 | ||
| >2 kinds of comorbidities | 1.154 (0.710–1.875) | 0.562 | ||
Figure 1The nomogram for calculating risk of postoperative anemia of patients who underwent TKA.
Figure 2The receiver operating characteristic (ROC) curve of training cohort (A) validation cohort (B), the calibration curve of training cohort (C) and validation cohort (B), and decision curve analysis (DCA) of training set (E).